Yankees Score with ...
Health Care: Drugs
Halozyme Therapeutics Inc. (HALO: NASDAQ)
$7.42 -0.03 | -0.40%
05/24/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 99.90M | 52.83M | 83.26M | 67.46M |
| Receivables | 15.70M | 2.26M | 2.33M | 4.24M |
| Inventories | 2.67M | 567.26K | 193.42K | 1.16M |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 131.03M | 63.99M | 89.50M | 74.44M |
| Property, Plant & Equipment, Gross | 10.38M | 7.52M | 6.52M | 6.15M |
| Accumulated Depreciation & Depletion | 6.68M | 5.75M | 4.68M | 3.45M |
| Property, Plant & Equipment, Net | 3.70M | 1.77M | 1.85M | 2.71M |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Assets | 3.70M | 1.77M | 1.85M | 2.71M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 134.73M | 65.76M | 91.35M | 77.15M |
| Accounts Payable | 2.27M | 7.56M | 3.82M | 2.82M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 18.95M | 17.30M | 15.34M | 14.40M |
| Long Term Debt | 29.66M | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 474.39K | 859.83K |
| Other Non-Current Liabilities | 37.27M | 37.56M | 55.18M | 54.99M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 66.93M | 37.56M | 55.65M | 55.85M |
| Total Liabilities | 85.87M | 54.86M | 70.99M | 70.25M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 48.85M | 10.90M | 20.35M | 6.90M |
| Common Par | 112.71K | 103.99K | 100.58K | 91.68K |
| Additional Paid In Capital | 347.31M | 255.82M | 245.50M | 178.82M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -298.57M | -245.02M | -225.25M | -172.01M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Capitalization | 78.52M | 10.90M | 20.35M | 6.90M |
| Total Equity | 48.85M | 10.90M | 20.35M | 6.90M |
| Total Liabilities & Stock Equity | 134.73M | 65.76M | 91.35M | 77.15M |
| Total Common Shares Outstanding | 112.71M | 103.99M | 100.58M | 91.68M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 111.08M | 102.57M | 94.36M | 86.70M |
| Diluted Weighted Shares Outstanding | 111.08M | 102.57M | 94.36M | 86.70M |
| Number of Employees | 152 | 135 | 102 | 139 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with HALO
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- UserWatch
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks With Big Insider Buy...
- Contributor3 Stocks to Buy for Less Th...
- UserGFNN Stockdiagnostics 6
- ContributorStocks With Big Insider Buy...
- ContributorStocks At New 52-Week Highs...
Latest HALO Headlines from TheStreet
- Ahead Of The Trend: 7 Rallying Stocks With Institutional Selling And Short Increases 05.23.13 | 02:05 pm
- Quick Take: The Next Big Thing in Biotech 05.17.13 | 10:05 am
- Biotech's Next Big Thing ASCO II
05.16.13 | 02:05 pm - 10 ASCO '13 Abstracts You Can Read Right Now 05.15.13 | 06:05 pm
- Short Interest Increases 11.2% For HALO 05.10.13 | 03:05 pm
- 4 Under-$10 Stocks Making Big Moves 04.23.13 | 03:04 pm
- HALO Makes Bullish Cross Above Critical Moving Average 04.23.13 | 11:04 am
- 7 Stocks Under $10 Moving Higher 11.15.12 | 03:11 pm
- 5 Stocks With Big Insider Buying 08.29.12 | 11:08 am
- Halozyme Therapeutics Management Discusses Q2 2012 Results - Earnings Call Transcript 08.06.12 | 07:08 pm
Press Releases for HALO
- Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer - PR Newswire 05.23.13 | 08:05 am
- Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society Of Clinical Oncology Annual Meeting - PR Newswire 05.15.13 | 06:05 pm
- Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference - PR Newswire 05.07.13 | 04:05 pm
- Halozyme To Host First Quarter 2013 Financial Results Conference Call - PR Newswire 05.01.13 | 04:05 pm
- Halozyme Initiates Randomized Phase 2 Trial Of PEGPH20 In Pancreatic Cancer - PR Newswire 04.23.13 | 08:04 am
- Halozyme Therapeutics Names Matt Posard To Board Of Directors - PR Newswire 03.28.13 | 04:03 pm
- Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union - PR Newswire 03.22.13 | 08:03 am
- Halozyme Therapeutics To Present At The Barclays 2013 Global Healthcare Conference - PR Newswire 03.05.13 | 04:03 pm
- Halozyme To Host Fourth Quarter And 2012 Year-End Financial Results Conference Call - PR Newswire 02.19.13 | 04:02 pm
- Halozyme Therapeutics Issues Financial Guidance For 2013 - PR Newswire 01.07.13 | 07:01 am
Partner Headlines for HALO
- Halozyme Therapeutics Earnings: Here’s Why Investors are Ambivalent Now - Wall St. Cheat Sheet 05.08.13 | 07:05 am
- Moves in Smaller Health Care Stocks (ANAC, HALO, PBYI, QCOR) - Benzinga 03.23.13 | 11:03 am
- Market Wrap for Friday, March 22: Stocks Rise on Hopes of Bailout Deal for Cyprus - Benzinga 03.22.13 | 04:03 pm
- Pertaining to Relief for ViroPharma - Analyst Blog - NASDAQ 09.25.12 | 07:09 pm
- ViroPharma Misses Zacks Estimates - Analyst Blog - Zacks 08.10.12 | 09:08 am
- VPHM Manufacturing Process Approved - Analyst Blog - Zacks 08.07.12 | 07:08 pm
- Bad News for ViroPharma - Analyst Blog - Zacks 08.03.12 | 06:08 pm
- After Hours Most Active for Aug 1, 2012 : SAN, GMCR, NOK, FSLR, BBVA, SBUX, BAC, JNJ, LEN, HALO, QQQ, SPLS - NASDAQ 08.01.12 | 08:08 pm
- Rituxan And Its Biosimilar Competitors - Seeking Alpha 07.30.12 | 09:07 am
- Healthcare Biz Recap: GlaxoSmithKline BUYS Drugs, Sanofi Gains Traction - Wall St. Cheat Sheet 06.12.12 | 06:06 am
